Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

Zhiwei Chen,1,* Shengping Shen,1,* Wenbo Shi,1,* Gening Jiang,2 Xin Wang,3 Hong Jian,1 Zhen Zhou,1 Zhengping Ding,1 Shun Lu11Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, People’s Republic of China; 2Department of Thoracic Surgery,...

Full description

Bibliographic Details
Main Authors: Chen Z, Shen S, Shi W, Jiang G, Wang X, Jian H, Zhou Z, Ding Z, Lu S
Format: Article
Language:English
Published: Dove Medical Press 2019-07-01
Series:Cancer Management and Research
Subjects:
non-small cell lung cancer (NSCLC)
neoadjuvant
erlotinib
gemcitabine
platinum
objective response rate
progression-free survival
overall survival
Online Access:https://www.dovepress.com/intercalated-combination-of-chemotherapy-and-erlotinib-for-stage-iiia--peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/intercalated-combination-of-chemotherapy-and-erlotinib-for-stage-iiia--peer-reviewed-article-CMAR

Similar Items